Skip to main content

Advertisement

SpringerLink
Log in

Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

We aimed to elucidate whether serum VEGFR2 concentration before and after transarterial chemoembolization (TACE) can predict survival in patients with unresectable hepatocellular carcinoma (HCC). Serum VEGFR2 concentrations were serially measured in 169 patients with advanced HCC before and after TACE. We defined a decrease in the serum VEGFR2 level >10 % from the pretreatment level as response. Serum VEGFR2 concentrations decreased in 44 (26.0 %) patients at week 4. Patients who had a VEGFR2 response at week 4 had a longer median survival than those who did not have a VEGFR2 decrease (19.0 vs. 9.8 months, p < 0.001). Clinical variables associated with OS in addition to VEGFR2 response also included extrahepatic metastases (p = 0.005) and vascular invasion (p = 0.035). VEGFR2 decrease after TACE (p = 0.012) and presence of extrahepatic metastases (p = 0.02) were independently associated with OS by multivariate analysis. A serum VEGFR2 concentration decrease at 4 weeks after TACE may predict favorable overall survival in patients with advanced HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–55.

    Article  PubMed  Google Scholar 

  2. Wild CP, Hall AJ. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res. 2000;462:381–93.

    Article  CAS  PubMed  Google Scholar 

  3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.

    Article  PubMed  Google Scholar 

  4. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–42.

    Article  CAS  PubMed  Google Scholar 

  5. Tang ZY. Hepatocellular carcinoma surgery—review of the past and prospects for the 21st century. J Surg Oncol. 2005;91:95–6.

    Article  PubMed  Google Scholar 

  6. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519–24.

    Article  PubMed  Google Scholar 

  7. Tan CK, Law NM, Ng HS, Machin D. Simple clinical prognostic model for hepatocellular carcinoma in developing countries and its validation. J Clin Oncol. 2003;21:2294–8.

    Article  PubMed  Google Scholar 

  8. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–57.

    Article  CAS  PubMed  Google Scholar 

  9. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 2009;6:569–79.

    Article  CAS  PubMed  Google Scholar 

  10. Huang J, Zhang X, Tang Q, Zhang F, Li Y, Feng Z, Zhu J. Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma. J Clin Pathol. 2011;64:343–8.

    Article  CAS  PubMed  Google Scholar 

  11. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.

    Article  PubMed  Google Scholar 

  12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.

    Article  CAS  PubMed  Google Scholar 

  13. Sakurai T, Kudo M. Signaling pathways governing tumor angiogenesis. Oncology-Basel. 2011;81(Suppl 1):24–9.

    Article  CAS  Google Scholar 

  14. Shim JH, Park JW, Kim JH, An M, Kong SY, Nam BH, Choi JI, Kim HB, Lee WJ, Kim CM. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci. 2008;99:2037–44.

    CAS  PubMed  Google Scholar 

  15. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol. 2004;10:2878–82.

    CAS  PubMed  Google Scholar 

  16. Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol. 2008;49:523–9.

    Article  CAS  PubMed  Google Scholar 

  17. Xu M, Xie XH, Xie XY, Xu ZF, Liu GJ, Zheng YL, Huang GL, Wang W, Zheng SG, Lu MD. Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo. Acta Radiol. 2013;54:199–204.

    Article  PubMed  Google Scholar 

  18. Tsuchiya K, Asahina Y, Matsuda S, Muraoka M, Nakata T, Suzuki Y, Tamaki N, Yasui Y, Suzuki S, Hosokawa T, Nishimura T, Ueda K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Izumi N. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. Cancer. 2013;120:229–37.

    Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Interventional Radiology, Cancer Center, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

    You-Bing Zheng, Wei Zhao, Bing Liu, Jian-Wen Huang, Xu He, Yong Li, Bao-Shan Hu & Li-Gong Lu

  2. Southern Medical University, Guangzhou, China

    You-Bing Zheng & Wei Zhao

  3. Department of Cardiology, Hainan Provincial People Hospital, Hainan, China

    Qing-Wen Meng

Authors
  1. You-Bing Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qing-Wen Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bing Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jian-Wen Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xu He
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bao-Shan Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Li-Gong Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Li-Gong Lu.

Additional information

You-Bing Zheng and Qing-Wen Meng have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zheng, YB., Meng, QW., Zhao, W. et al. Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Med Oncol 31, 843 (2014). https://doi.org/10.1007/s12032-014-0843-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0843-5

Keywords

Search

Navigation